vs
Primerica, Inc.（PRI）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
Primerica, Inc.的季度营收约是Revvity的1.1倍（$853.7M vs $772.1M），Primerica, Inc.净利率更高（23.1% vs 12.7%，领先10.3%），Primerica, Inc.同比增速更快（11.0% vs 5.9%），过去两年Revvity的营收复合增速更高（9.0% vs 7.2%）
Primerica, Inc.是一家采用多层次营销模式的金融服务机构，业务覆盖美国与加拿大市场，主要面向当地中等收入家庭提供保险、投资等多元化金融产品，满足客户的风险保障与差异化财富管理需求。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
PRI vs RVTY — 直观对比
营收规模更大
PRI
是对方的1.1倍
$772.1M
营收增速更快
PRI
高出5.2%
5.9%
净利率更高
PRI
高出10.3%
12.7%
两年增速更快
RVTY
近两年复合增速
7.2%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $853.7M | $772.1M |
| 净利润 | $197.0M | $98.4M |
| 毛利率 | — | — |
| 营业利润率 | 28.9% | 14.5% |
| 净利率 | 23.1% | 12.7% |
| 营收同比 | 11.0% | 5.9% |
| 净利润同比 | 17.9% | 3.9% |
| 每股收益（稀释后） | $6.11 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PRIRVTY
| Q4 25 | $853.7M | $772.1M | ||
| Q3 25 | $839.9M | $698.9M | ||
| Q2 25 | $793.3M | $720.3M | ||
| Q1 25 | $804.8M | $664.8M | ||
| Q4 24 | $768.8M | $729.4M | ||
| Q3 24 | $774.1M | $684.0M | ||
| Q2 24 | $803.4M | $691.7M | ||
| Q1 24 | $742.8M | $649.9M |
净利润PRIRVTY
| Q4 25 | $197.0M | $98.4M | ||
| Q3 25 | $206.8M | $46.7M | ||
| Q2 25 | $178.3M | $53.9M | ||
| Q1 25 | $169.1M | $42.2M | ||
| Q4 24 | $167.1M | $94.6M | ||
| Q3 24 | $164.4M | $94.4M | ||
| Q2 24 | $1.2M | $55.4M | ||
| Q1 24 | $137.9M | $26.0M |
毛利率PRIRVTY
| Q4 25 | — | — | ||
| Q3 25 | — | 53.6% | ||
| Q2 25 | — | 54.5% | ||
| Q1 25 | — | 56.5% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 56.3% | ||
| Q2 24 | 98.0% | 55.7% | ||
| Q1 24 | 98.2% | 54.6% |
营业利润率PRIRVTY
| Q4 25 | 28.9% | 14.5% | ||
| Q3 25 | 32.3% | 11.7% | ||
| Q2 25 | 29.6% | 12.6% | ||
| Q1 25 | 27.5% | 10.9% | ||
| Q4 24 | 64.7% | 16.3% | ||
| Q3 24 | 32.9% | 14.3% | ||
| Q2 24 | 1.0% | 12.4% | ||
| Q1 24 | 24.1% | 6.8% |
净利率PRIRVTY
| Q4 25 | 23.1% | 12.7% | ||
| Q3 25 | 24.6% | 6.7% | ||
| Q2 25 | 22.5% | 7.5% | ||
| Q1 25 | 21.0% | 6.4% | ||
| Q4 24 | 21.7% | 13.0% | ||
| Q3 24 | 21.2% | 13.8% | ||
| Q2 24 | 0.1% | 8.0% | ||
| Q1 24 | 18.6% | 4.0% |
每股收益（稀释后）PRIRVTY
| Q4 25 | $6.11 | $0.86 | ||
| Q3 25 | $6.35 | $0.40 | ||
| Q2 25 | $5.40 | $0.46 | ||
| Q1 25 | $5.05 | $0.35 | ||
| Q4 24 | $4.92 | $0.77 | ||
| Q3 24 | $4.83 | $0.77 | ||
| Q2 24 | $0.03 | $0.45 | ||
| Q1 24 | $3.93 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $756.2M | $919.9M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $2.4B | $7.3B |
| 总资产 | $15.0B | $12.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资PRIRVTY
| Q4 25 | $756.2M | $919.9M | ||
| Q3 25 | $644.9M | $931.4M | ||
| Q2 25 | $621.2M | $991.8M | ||
| Q1 25 | $625.1M | $1.1B | ||
| Q4 24 | $687.8M | $1.2B | ||
| Q3 24 | $550.1M | $1.2B | ||
| Q2 24 | $627.3M | $2.0B | ||
| Q1 24 | $593.4M | $1.7B |
股东权益PRIRVTY
| Q4 25 | $2.4B | $7.3B | ||
| Q3 25 | $2.3B | $7.4B | ||
| Q2 25 | $2.3B | $7.6B | ||
| Q1 25 | $2.3B | $7.6B | ||
| Q4 24 | $2.3B | $7.7B | ||
| Q3 24 | $1.9B | $7.9B | ||
| Q2 24 | $2.1B | $7.9B | ||
| Q1 24 | $2.2B | $7.8B |
总资产PRIRVTY
| Q4 25 | $15.0B | $12.2B | ||
| Q3 25 | $14.8B | $12.1B | ||
| Q2 25 | $14.8B | $12.4B | ||
| Q1 25 | $14.6B | $12.4B | ||
| Q4 24 | $14.6B | $12.4B | ||
| Q3 24 | $14.8B | $12.8B | ||
| Q2 24 | $14.6B | $13.4B | ||
| Q1 24 | $14.9B | $13.4B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $338.2M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | — | $161.8M |
| 自由现金流率自由现金流/营收 | — | 21.0% |
| 资本支出强度资本支出/营收 | — | 2.6% |
| 现金转化率经营现金流/净利润 | 1.72× | 1.85× |
| 过去12个月自由现金流最近4个季度 | — | $509.4M |
8季度趋势，按日历期对齐
经营现金流PRIRVTY
| Q4 25 | $338.2M | $182.0M | ||
| Q3 25 | $202.9M | $138.5M | ||
| Q2 25 | $162.6M | $134.3M | ||
| Q1 25 | $197.5M | $128.2M | ||
| Q4 24 | $270.6M | $174.2M | ||
| Q3 24 | $207.3M | $147.9M | ||
| Q2 24 | $173.3M | $158.6M | ||
| Q1 24 | $210.9M | $147.6M |
自由现金流PRIRVTY
| Q4 25 | — | $161.8M | ||
| Q3 25 | — | $120.0M | ||
| Q2 25 | — | $115.5M | ||
| Q1 25 | — | $112.2M | ||
| Q4 24 | — | $149.8M | ||
| Q3 24 | — | $125.6M | ||
| Q2 24 | — | $136.6M | ||
| Q1 24 | — | $129.7M |
自由现金流率PRIRVTY
| Q4 25 | — | 21.0% | ||
| Q3 25 | — | 17.2% | ||
| Q2 25 | — | 16.0% | ||
| Q1 25 | — | 16.9% | ||
| Q4 24 | — | 20.5% | ||
| Q3 24 | — | 18.4% | ||
| Q2 24 | — | 19.7% | ||
| Q1 24 | — | 20.0% |
资本支出强度PRIRVTY
| Q4 25 | — | 2.6% | ||
| Q3 25 | — | 2.6% | ||
| Q2 25 | — | 2.6% | ||
| Q1 25 | — | 2.4% | ||
| Q4 24 | — | 3.4% | ||
| Q3 24 | — | 3.3% | ||
| Q2 24 | — | 3.2% | ||
| Q1 24 | — | 2.7% |
现金转化率PRIRVTY
| Q4 25 | 1.72× | 1.85× | ||
| Q3 25 | 0.98× | 2.97× | ||
| Q2 25 | 0.91× | 2.49× | ||
| Q1 25 | 1.17× | 3.03× | ||
| Q4 24 | 1.62× | 1.84× | ||
| Q3 24 | 1.26× | 1.57× | ||
| Q2 24 | 147.98× | 2.87× | ||
| Q1 24 | 1.53× | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PRI
| Revenues From Sources Other Than Contracts With Customers | $445.9M | 52% |
| Investment And Savings Products Segment Revenues | $340.3M | 40% |
| Other | $56.5M | 7% |
| Segment Revenues From Contracts With Customers | $11.0M | 1% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
